Esperion Therapeutics Inc. (ESPR)
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $8.25
Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down
Esperion Therapeutics' Q4 revenues surge 144% to $168.4M but EPS of 22 cents misses estimates. Shares fall as mixed results weigh on sentiment.
Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript
Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript
Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates
Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to a loss of $0.1 per share a year ago.
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M
Esperion to buy Corstasis for $75M in cash, adding FDA-approved Enbumyst nasal spray to its cardiovascular franchise. The deal is likely to be closed in Q2.
Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript
Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript
Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy?
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript
Esperion Therapeutics, Inc. ( ESPR ) Jefferies London Healthcare Conference 2025 November 18, 2025 3:00 AM EST Company Participants Benjamin Halladay - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good morning. Welcome to the Jefferies London Healthcare Conference.
Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript
Esperion Therapeutics, Inc. ( ESPR ) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health November 11, 2025 2:00 PM EST Company Participants Sheldon Koenig - President, CEO & Director LeAnne Bloedon Conference Call Participants Dharmesh Patel Fatima Rodriguez Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Jason Zemansky - BofA Securities, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Presentation Operator Good day, everyone.
